Vectors Research Management’s Filana Therapeutics FLNA Stock Holding History

Vectors Research Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-75	Closed	-$2K	–	413
2022 Q2	$2K	Hold	75	–	–	﹤0.01%	475
2022 Q1	$3K	Hold	75	–	–	﹤0.01%	427
2021 Q4	$3K	Hold	75	–	–	﹤0.01%	548
2021 Q3	$5K	Hold	75	–	–	﹤0.01%	420
2021 Q2	$6K	Hold	75	–	–	﹤0.01%	433
2021 Q1	$3K	Buy	+75	New	+$2.95K	﹤0.01%	417

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vectors Research Management's FLNA Position: Q3 2022 in Review

Vectors Research Management sold out of Filana Therapeutics (FLNA) in Q3 2022, closing a stake of 75 shares — an estimated $2K sold.

Vectors Research Management first reported a position in FLNA in Q1 2021 and held it in 6 quarters. The position peaked at $6K in Q2 2021. 175 funds tracked by Wall St. Rank hold FLNA as of Q3 2022.

Vectors Research Management reported no remaining Filana Therapeutics position as of Q3 2022 after selling out during the quarter.
Vectors Research Management sold 75 Filana Therapeutics shares in Q3 2022, an estimated $2K.
Vectors Research Management first reported a position in Filana Therapeutics in Q1 2021 and held it in 6 quarters.
Vectors Research Management's Filana Therapeutics position peaked at $6K in Q2 2021.
175 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.